Novo and Vivo Capital led a $200m Series A round in Esco Lifesciences Group.

CIC Capital, Novo and Vivo Capital led a $200m Series A round in Esco Lifesciences Group, a provider of life sciences tools and services, with participation from EDBI. The financing will enable Esco to strengthen its position through organic and external growth and transformation, as well as invest in China, thus addressing some of the most dynamic market segments and geographies.